PBAC's latest decision on Fludarabine phosphate: Recommended with restriction (2008). Considered for Treatment of B-cell chronic lymphocytic leukaemia (CLL) in combination with cyclophosphamide in patients with advanced disease (Binet Stage B or C) or evidence of progressive Stage A disease.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
$45k/QALY
Range: $15k/QALY–$45k/QALY
Submissions
1
first 2008
Submissions
1
2008 → 2008
Eligible population
Patients with B-cell chronic lymphocytic leukaemia with advanced disease (Binet Stage B or C) or evidence of progressive Stage A disease, with CLL diagnosed by lymphocytosis (≥5 × 10⁹ lymphocytes/L) and clonal B-cell population (CD5/CD19) documented by flow cytometry.